Finanzieller Lagebericht

In 2023, Octapharma celebrated 40 years of innovation and success since our company was founded in 1983 by two men with a shared vision to provide haemophilia patients with a safe and efficacious factor VIII (FVIII) replacement therapy. It was also a year of extraordinary achievement.

Auf unseren Erfolg aufbauen

Brief von unserem Inhaber

Celebrating our milestones 

It all started in 1983 with a single idea: people with haemophilia deserve access to better products. Today we help thousands of patients worldwide.  

Celebrating our milestones

Octapharma demonstrates commitment to improving haemophilia A treatment at EAHAD

Octapharma demonstrates commitment to improving haemophilia A treatment at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Update of Summary of Product Characteristics for Nuwiq® 

Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis

Positive results for fibryga published in the Journal of Thrombosis and Haemostasis

The final results of the Phase 3 clinical trial investigating fibryga® for the treatment of bleeding and surgical prophylaxis in patients with congenital fibrinogen deficiency (FORMA-02) has been published in the Journal of Thrombosis and Haemostasis (JTH).  FORMA-02

Positive results for fibryga, fibrinogen deficiency, Journal of Thrombosis and Haemostasis. FORMA-02

Positive results for fibryga® in the treatment of bleeding and surgical prophylaxis in patients with congenital fibrinogen deficiency (FORMA-02) published in the Journal of Thrombosis and Haemostasis

Patienten Blut Management - Ein neuer Behandlungsstandard

Patientenblut Management - Ein neuer Behandlungsstandard

Octapharma Group reports strong results for 2018

ommenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products."

Octapharma Group publishes 2017 annual results

Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017.

Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million

Rechtzeitige Hilfe für kristisch kranke Patienten

Timely help for critically ill patients 

Final results from the NuProtect study demonstrating efficacy of Nuwiq

Final results from the NuProtect study demonstrating efficacy of Nuwiq® in PUPs

Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019

Octapharma Group publishes 2016 annual results 

The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015.

Octapharma Group publishes 2016 annual results

Octapharma Group publishes 2016 annual results reporting revenue of €1.6 billion and operating income of €383 million

New Data on Haemophilia A or von Willebrand Disease at ISTH 2019

Octapharma to Present New Data on Management of People with Haemophilia A or von Willebrand Disease at ISTH 2019

Octapharma share promising preclinical data for SubQ-8

Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK.

Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018

Vertrauen und Entscheidungsfähigkeit

Gennadiy Galstyan, MD, PhD, heads the Department of Intensive Care at the National Research Center for Hematology in Russia.

Vertrauen, Entscheidungsfähigkeit und medizinische Kompetenz sind entscheidend in der Intensivpflege.

Jahresbericht 2019

Low inhibitor rate with octanate® in previously untreated patients

Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia.

Low inhibitor rate with octanate®

Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

Final results from the NuProtect study

Highlighting the NuProtect study at ASH 2019

Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019

Fany Chauvel, Corporate Head of People, Organisation and Culture

Per Eriksson, Head of Market Communications

Schaffung eines Unternehmens, das von Daten und digitalen Instrumenten angetrieben wird 

Die pharmazeutische Industrie wächst und entwickelt sich rasch, daher wird es für Unternehmen immer wichtiger, Talente zu gewinnen und zu binden

Aufbau des Unternehmens von morgen

Octapharma activities prominent at the upcoming 2017 ISTH Congress

Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress will be held in Berlin, Germany from 8–13 July. Octapharma is delighted to be a Platinum Sponsor of the Congress.

Octapharma activities prominent at 2017 ISTH Congress

Octapharma activities prominent at the upcoming 2017 ISTH Congress in Berlin, Germany

update on the development of SubQ-8 ISTH 2019

Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019

Wir investieren, um den Erfolg von Octapharma auch in Zukunft zu sichern

Letter from the Chief Financial Officer, Roger Mächler - Annual Report 2019

Octapharma to build new multi-use venue

Octapharma to invest Euro 21 million to build a new multi-use venue in Springe, Germany. Octapharma has confirmed to invest Euro 21 million to build a new multi-function facility in Springe, Germany

Octapharma has confirmed to invest Euro 21 million to build a new multi-function facility in Springe, Germany.

Octapharma to invest Euro 21 million to build a new multi-use venue in Springe, Germany

Die Geschichte von fibryga®

Mitglieder des Octapharma fibryga®-Teams

The science of teamwork: the story of Octapharma’s high-purity human fibrinogen concentrate

Octapharma present new data on the benefits of Nuwiq®

Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK.

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Octapharma’s fibryga® receives European label extension to treat acquired fibrinogen deficiency (AFD) 

Fibryga® receives European label extension to treat acquired fibrinogen deficiency (AFD) 

Octapharma symposium at ISTH Berlin

Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany.

Octapharma symposium at ISTH Berlin supports progress in lifelong treatment of high-risk patients with von Willebrand disease (VWD) and haemophilia A

New data ISTH 2019 

Octapharma presents new data on the benefits of Nuwiq® in patients with haemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Cong

Octapharma presents new data on the benefits of Nuwiq® in patients with haemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress

Unsere Produkte werden auch kommenden Generationen zugute kommen

Wolfgang Marguerre, Chairman and CEO, Octapharma Group

Letter from the chairman and CEO, Octapharma Group, Wolfgang Marguerre - Annual Report 2019

Weiterdenken

Thomas, zusammen mit seinem Team sorgen für die Virussicherheit bei Octapharma.

Octapharma führt routinemäßig an allen Plasmapools PCR-Tests auf HIV, HAV, HBV und Parvo-B19-Viren sowie auf HCV durch.

Testing boundaries, PCR testing plays a key role in product safety.

Testing boundaries

Octapharma announces approval of new Nuwiq® product strengths

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®.

Octapharma announces approval of new Nuwiq® product strengths in Europe

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A

Octapharma announces publication of data on fibryga

Octapharma announces publication of data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

New data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

Octapharma Group delivered strong growth in both sales and operating income in 2019

Octapharma Group delivered strong in 2019

International Early Career Program

Fabians Weg in die Biomedizintechnik und das Traineeprogramm von Octapharma

Spatenstich in Wien-Favoriten: Octapharma baut Produktionsstandort stark aus

 Under the Spotlight: Auf dem 15. Jahreskongress der European Association for Haemophilia and Allied Disorders (EAHAD) beleuchtet Octapharma die Herausforderungen beim Umgang mit Inhibitoren bei Hämophilie A

EAHAD 2022

Auf dem 15. Jahreskongress der European Association for Haemophilia and Allied Disorders (EAHAD) beleuchtet Octapharma die Herausforderungen beim Umgang mit Inhibitoren bei Hämophilie A

William, der vor zwei Jahren zum ersten Mal Plasma gespendet hat, nachdem er von seinem Schwager auf die Idee gebracht wurde, spendet jetzt zweimal pro Woche.

Auf einen Blick

Die Spenderzentren von Octapharma führten strenge neue Sicherheitsmaßnahmen ein, um eine COVID-19-Pandemie zu verhindern, darunter das Tragen von Masken, verstärkte Hygiene und Abstand Halten.

Plasma spenden und Leben retten  

Jahresbericht 2020

Plasma spenden und Leben retten

Studie legt nahe, dass 4F-PCC als Ersatz für gefrorenes Plasma bei der Behandlung von Blutungen in der Herzchirurgie verwendet werden kann

Studienergebnisse zu 4F-PCC als Ersatz für gefrorenes Plasma

Studienergebnisse zu 4F-PCC als Ersatz für gefrorenes Frischplasma bei der Behandlung von Blutungen in der Herzchirurgie

Studie zu 4F-PCC als Ersatz für Plasma

Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress, Octapharma’s active involvement includes two sponsored scientific symposia.

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® 

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data

Fibryga® receives Swissmedic approval

Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies

Octapharma receives Swissmedic approval for fibryga®

GTH 2024 in Wien: Octapharma-Symposium beleuchtet spezielle Gruppen innerhalb der Hämophilie und Von-Willebrand-Erkrankung

GTH 2024

GTH 2024 in Wien: Octapharma-Symposium beleuchtete spezielle Gruppen innerhalb der Hämophilie und Von-Willebrand-Erkrankung

EAHAD 2024: Octapharma präsentiert neue klinische und wissenschaftliche Daten im Bereich Von-Willebrand-Erkrankung und Hämophilie A

 Octapharma kündigte heute ein Satellitensymposium und eine Posterpräsentation auf dem 14. Jahreskongress der European Association for Haemophilia and Allied Disorders (EAHAD) an, die vom 3. bis 5. Februar 2021 virtuell stattfinden wird. 

Sich dem Wandel anpassen - WHD 2021

Welttag der Hämophilie 2021

WHD 2021

Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017.

Octapharma underlines strong commitment to haemophilia A patients

Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®

Octapharma announced today the launch of the Canadian PREVAIL (Immune Tolerance Induction in Hemophilia A Patients using wilate®) study for patients with Hemophilia A.

New Canadian study to improve eradication of inhibitors in Hemophilia A patients

New Canadian study to improve eradication of inhibitors

Das neue International Early Career Program (IECP)

Maikos Traineeship - ein Weg voller Erfahrungen und maßgeschneiderter Aktivitäten  

Live-Web-Seminar „Schmerz lass nach! Atemübung, Bewegung, Cannabis – verschiedene Wege aus dem Schmerz bei Hämophilie“ am 08.06.2022

Live-Web-Seminar „Schmerz lass nach! Atemübung, Bewegung, Cannabis – verschiedene Wege aus dem Schmerz bei Hämophilie“  am 08.06.2022

Live Web Seminar Schmerz lass nach

Octapharma gab heute bekannt, dass neue klinische und wissenschaftliche Erkenntnisse aus dem Hämatologie-Portfolio des Unternehmens, einschließlich Nuwiq®, wilate®, octanate® und octanine®F, auf dem bevorstehenden virtuellen Kongress der International Society on Thrombosis and Haemostasis (ISTH), der vom 17. bis 21. Ju

Octapharmas kontinuierliches Engagement wird auf dem ISTH-Kongress 2021 vorgestellt

Octapharma präsentiert Einsatz für Patienten mit Blutgerinnungsstörungen auf dem ISTH-Kongress 2021

ISTH 2021 new clinical and scientific findings encompassing the Haematology portfolio

Patient Blood Management (PBM) is a multidisciplinary, evidence-based approach to individualising patient care. 

Patient Blood Management – A new standard of care

Patient Blood Management – Ein neuer Versorgungsstandard

Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously untreated patients (PUPs), on August 16th 2017 as an Early View article in the internationally renowned medical journal Haemophilia.

Publication of clinical data demonstrating low immunogenicity

Publication of clinical data demonstrating low immunogenicity and excellent efficacy of Nuwiq® in previously untreated patients

Publication of clinical data demonstrating low immunogenicity and excellent efficacy of Nuwiq®

Entwicklungsmöglichkeiten bei Octapharma: Eine Trainee-Reise mit Maja Warlin

Live-Web-Seminar „Frauen & VWS: It’s not a Man’s World“ am 21.09.2021

Seminar „Frauen & VWS: It’s not a Man’s World“ am 21.09.2021

Live-Web-Seminar „Frauen & VWS: It’s not a Man’s World“ am 21.09.2021 

Seminar Frauen & VWS: It's not a Man's World

EAHAD 2021

Octapharma zeigt auf dem 14. EAHAD-Jahreskongress sein kontinuierliches Engagement für die langfristige Verbesserung der Gesundheit von Menschen mit Hämophilie A

Thoralf Petzold mit den Schlüsseln zu den verfügbaren Wohnungen

Octapharma Dessau arbeitet mit den örtlichen Behörden zusammen, um Flüchtlingen, die vor dem Krieg in der Ukraine fliehen, möblierte Wohnungen zur Verfügung zu stellen.

Wohnraum für ukrainische Flüchtlinge

Octapharma Dessau richtet Wohnraum für ukrainische Flüchtlinge her

Wohnraum für urkainische Flüchtlinge

Die Octapharma Handelsges.m.b.H. freut sich Ihnen mitzuteilen, dass unser neues 16,5%iges Immunglobulin zur subkutanen Applikation ab Januar 2022 erhältlich ist.

cutaquig® - Neues 16,5%iges subkutanes Immunglobulin

Cutaquig ab 01-2022 erhältlich

William, who first donated two years ago after getting the idea from his brother-in-law, now gives plasma twice a week.

At a glance

Octapharma donor centres introduced stringent new safety measures to prevent COVID-19 pandemic, including the wearing of masks, increased sanitation and social distancing. 

Donating plasma and saving lives  

Annual Report 2020

Ashleigh Kline and her team had to fundamentally change the way they worked in response to COVID-19.

Plasma donation at a glance

As COVID-19 began to spread across the globe, Octapharma employees went the extra mile to secure that we could continue to deliver our products to patients.

Ensuring plasma supplies during COVID-19

Protecting our patients: ensuring plasma supplies during COVID-19

Live-Web-Seminar „Frauen & Hämophilie: Was bedeutet es Konduktorin zu sein? 

Seminar „Frauen & Hämophilie

Seminar Frauen und Hämophilie

GTH 2022: Octapharma präsentiert am 01. März 2022 live vor Ort in Leipzig in einem Symposium „Wichtige Facetten der Therapieentscheidung bei Hämophilie A“

GTH 2022

Octapharma also conducted a retrospective data analysis of a COVID-19 patient cohort in Turkey.

As COVID-19 began to evolve into a global pandemic this year, Octapharma moved rapidly to find new ways in which to protect patients and employees. In the space of just a few weeks in March, the company had created a special project team to confront the disease.

Committed to the fight against COVID-19 

Letter from the chairman and CEO, Octapharma Group, Wolfgang Marguerre - Annual Report 2020

Remaining strong, resilient and agile

Letter from the Chief Financial Officer, Roger Mächler - Annual Report 2020

Delivering strong performance in 2020

Symptoms of VWD

Friendly and easy-going, Kerri continues to manage everything with her characteristic optimism.

Treating VWD

When Kerri first heard about COVID-19, she didn’t immediately grasp the severity of the disease or how big an impact it would have on all our daily lives. But she quickly realised the possible implications for patients like herself. 

Facing VWD during COVID-19 as both a nurse and patient

CLL explained

“I am so lucky to have found myself surrounded by such support,” says Ingrid.

Treatment

In March 2003, Ingrid was diagnosed with Chronic Lymphocytic Leukaemia. “What was meant to be a reassuring check-up with my doctor turned my life upside down,” she remembers. 

Cancer was not part of the plan

PANS/PANDAS explained

Avery was treated with antibiotics for approximately eight months as well as given multiple supplements to help boost her immune system.

PANS/PANDAS symptoms

Avery (centre) with her older sister (left) and mother, Carrie (right).

It is estimated that up to one in 200 children have PANS. The medical options to treat this rare disease remain limited IVIg seems to offer a real breakthrough.

News

Octapharma weltweit

Über uns

Plasma

Produkte

Karriere

Service